In terms of chemotherapy, studies had suggested that low NLR patients treated with bevacizumab and low PLR patients treated with anti-EGFR had better prognosis and NLR was a prognostic biomarker for CRC patients receiving TAS- 102 treatment66, 67. This evidence concerns the gene EGFR and colorectal carcinoma.